March 2012
Volume 53, Issue 14
ARVO Annual Meeting Abstract  |   March 2012
To Evaluate Patient Outcomes Following Epithelium-on CXL In Patients Who Received The Treatment In One Or Both Eyes
Author Affiliations & Notes
  • Roy Rubinfeld
    Washington Eye Physicians and Surgeons, Chevy Chase, Maryland
  • William Trattler
    Center For Excellence in Eye Care, Miami, Florida
  • Gabriela Perez
    Ctr for Excellence in Eye Care, Miami, Florida
  • Charles J. Kaiser
    Center For Excellence in Eye Care, Miami, Florida
  • Aaleya Koreishi
    Cornea Associates of Texas, Dallas, Texas
  • Parag Majmudar
    Chicago Cornea, Chicago, Illinois
  • Randy J. Epstein
    Chicago Cornea, Chicago, Illinois
  • Shamik Bafna
    Cleveland Eye Clinic, Cleveland, Ohio
  • Ranjan Malahotra
    Ophthalmology Associates, St. Louis, Missouri
  • Footnotes
    Commercial Relationships  Roy Rubinfeld, CXL USA (E); William Trattler, CXL USA (C); Gabriela Perez, None; Charles J. Kaiser, CXL USA (C); Aaleya Koreishi, None; Parag Majmudar, None; Randy J. Epstein, None; Shamik Bafna, None; Ranjan Malahotra, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 6786. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Roy Rubinfeld, William Trattler, Gabriela Perez, Charles J. Kaiser, Aaleya Koreishi, Parag Majmudar, Randy J. Epstein, Shamik Bafna, Ranjan Malahotra; To Evaluate Patient Outcomes Following Epithelium-on CXL In Patients Who Received The Treatment In One Or Both Eyes. Invest. Ophthalmol. Vis. Sci. 2012;53(14):6786.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To evaluate patient outcomes following Epithelium-On CXL in patients who received the treatment in one or both eyes.

Methods: : Eyes enrolled in the study underwent Epithelial-On crosslinking, with preservative-free 0.1% isotonic riboflavin for 30 to 90 minutes. Riboflavin loading was stopped once the cornea was determined by slit lamp examination to be saturated. UV light was initiated for 30 minutes after ensuring that the minimum corneal thickness was at least 400 microns. Post-Op measures including corneal hysteresis (CH) and corneal resistance factor (CRF), Pentacam data, and uncorrected and best-spectacle corrected visual acuities were recorded. Eyes evaluated had a minimum follow-up visit of 3 months and a maximum follow up visit of 18.7 months.

Results: : There were 181 (127 male and 49 female) eyes pre-operatively with a follow-up range of 3 months minimum to 18.7 months maximum. The mean follow-up time was 10.85 months. 81% of these eyes had a pre-op diagnosis of keratoconus, 15% had post-LASIK Ectasia, and 2% had pellucid marginal degeneration. Average CH values increased post-operatively from 7.3 to 7.8 and average CRF values increased post-operatively from 5.9 to 7.8. Average refractive cylinder decreased from 4.52D to 3.96D. On Pentacam, average 2mm K Astigmatism decreased post-operatively from 5.47 to 4.66 and average Holladay Astigmatism decreased post-operatively from 3.18 to 2.19. 35.8% of eyes experienced no change in the number of lines of BSCVA and 46.4% of eyes gained 1 or more lines. 30.2% of eyes experienced a loss in one or more lines of BSCVA. Average BSCVA pre-Op was 20/145 and post-Op was 20/114.

Conclusions: : Epithelium-on corneal collagen cross-linking appears to be a safe and effective treatment for patients with corneal ecstatic disease.

Clinical Trial: : NCT01024322

Keywords: keratoconus 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.